Ryan John L 4

4 · Kadmon Holdings, Inc. · Filed Nov 9, 2021

Form 4

Period: 2021-11-09

Executive Vice President, CMO

Transactions

Disposition to Issuer
Stock Option (right to buy)
2021-11-09$5.16/sh−100,000$516,000→ 0 total
Exercise: $4.34Exp: 2030-01-27→ Common Stock, par value $0.001 (100,000 underlying)
Disposition to Issuer
Equity Appreciation Rights Unit
2021-11-09$3.50/sh−250$875→ 0 total
Exercise: $6.00Exp: 2024-12-16→ Common Stock, par value $0.001 (250 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$4.84/sh−100,000$484,000→ 0 total
Exercise: $4.66Exp: 2026-12-15→ Common Stock, par value $0.001 (100,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$5.86/sh−150,000$879,000→ 0 total
Exercise: $3.64Exp: 2027-12-08→ Common Stock, par value $0.001 (150,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$7.03/sh−50,000$351,500→ 0 total
Exercise: $2.47Exp: 2028-12-14→ Common Stock, par value $0.001 (50,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$5.54/sh−175,000$969,500→ 0 total
Exercise: $3.96Exp: 2031-01-08→ Common Stock, par value $0.001 (175,000 underlying)

Footnotes (2)

[F1]In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award.
[F2]Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR.

Documents

1 file